do not combine dpp-4 inhibitors with glp-1 receptor agonists guidance for type 2 diabetes management Insight into Structure Activity Relationship
Description
Marsico F, Paolillo S, Gargiulo P, Bruzzese D, DellAversana S, Esposito I, Renga F, Esposito L, Marciano C, Dellegrottaglie S, Iesu I, Perrone Filardi P

doi: 10.1172/jci.insight.133429 146 SalamehTSRheaEMTalbotKBanksWA

Heart rate, beta-blocker use, and outcomes of heart failure with reduced ejection fraction

Saito Y, Tanaka A, Imai T, Nakamura I, Kanda J, Matsuhisa M, et al
The cost of independent testing is minimal compared to the cost of a compromised study

GLP-1 receptor agonists may be appropriate second-line agents after metformin or even first-line in patients with established cardiovascular disease, chronic kidney disease, or when weight management is a priority